Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 4/20 | 0.50 |
| ▸ | AKT1 | P31749 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.47 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.47 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.47 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20500894 | 0.92 | MALT1 (0.51) | MALT1DRD2AKT1BRD4TPSAB1 | |
| SCHEMBL25974776 | 0.92 | MALT1 (0.52) | MALT1DRD2BRD4TPSAB1TPSD1 | |
| SCHEMBL8139824 | 0.91 | BRD4 (0.53) | MALT1DRD2BRD4TPSAB1TPSD1 | |
| SCHEMBL9773851 | 0.89 | TPSAB1 (0.54) | MALT1DRD2BRD4TPSAB1TPSD1 | |
| SCHEMBL31655700 | 0.89 | TPSAB1 (0.54) | MALT1DRD2BRD4TPSAB1TPSD1 | |
| SCHEMBL22291518 | 0.89 | TPSAB1 (0.54) | MALT1DRD2BRD4TPSAB1TPSD1 | |
| SCHEMBL24796373 | 0.88 | HEXA (0.58) | BRD4 | |
| SCHEMBL4392860 | 0.88 | MALT1 (0.49) | MALT1DRD2BRD4TPSAB1TPSD1 | |
| SCHEMBL21997347 | 0.87 | ALDH1A1 (0.55) | MALT1AKT1PDCD1CD274 | |
| SCHEMBL30675910 | 0.87 | BRD4 (0.51) | MALT1DRD2BRD4TPSAB1TPSD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2799431-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM Corporation (JP) | 2014-11-05 | — | — | EP | disclosed |
| US-20100069453-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-10-16 | — | — | US | disclosed |
| WO-2007056469-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| EP-0861243-B1 | HETEROCYCLIC COMPOUNDS AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-11-12 | — | — | EP | disclosed |
| US-6344462-B1 | Heterocyclic compounds as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-05 | — | — | US | disclosed |
| US-6100284-A | ANTIALLERGENS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-08-08 | — | — | US | disclosed |
| US-6008229-A | TREATING ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASE, SHOCK, PAIN | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-12-28 | — | — | US | disclosed |
| EP-0861243-A1 | HETEROCYCLIC COMPOUNDS AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-09-02 | — | — | EP | disclosed |
| WO-1997011069-A1 | HETEROCYCLIC COMPOUNDS AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-03-27 | — | — | WO | disclosed |
| US-4385181-A | CHAMICAL INTERMEDIATES FOR CEPHALOSPORINS | RHONE POULENC INDUSTRIES (FR) | 1983-05-24 | — | — | US | disclosed |
| US-4347359-A | CEPHALOSPORIN INTERMEDIATES | RHONE-POULENC INDUSTRIES (FR) | 1982-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069453-A1 | Certain Chemical Entities, Compositions, and Methods | KIF5B, KIF2C, PLK1 | MALT1 3821/4885DRD2 4544/4885AKT1 1836/4885 |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | MALT1 3821/4885DRD2 4544/4885AKT1 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.